Sarepta Therapeutics (NASDAQ:SRPT) Earns Neutral Rating from The Goldman Sachs Group
The Goldman Sachs Group reaffirmed their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $29.00 price objective on the biotechnology company’s stock. SRPT has been the topic of several other reports. Royal Bank Of Canada decreased their target price on shares […]
The Goldman Sachs Group reaffirmed their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $29.00 price objective on the biotechnology company’s stock. SRPT has been the topic of several other reports. Royal Bank Of Canada decreased their target price on shares […]
